<DOC>
	<DOCNO>NCT00972725</DOCNO>
	<brief_summary>The purpose study evaluate safety reactogenicity one booster dose HIV candidate vaccine administration one oral dose chloroquine .</brief_summary>
	<brief_title>Evaluation Immune Response HIV Candidate Vaccine After Administration One Chloroquine Dose</brief_title>
	<detailed_description>The Protocol Posting update follow Protocol amendment 1 , October 2009 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>A male female , include , 18 52 year age time vaccination . Written inform consent prior study related procedure subject . Subjects investigator believe comply requirement protocol . Good general health without significant medical history physical examination finding . Negative antiHBc antiHepatitis C Virus antibody . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception study completion . Previous participation completion study NCT00434512 . Cellular humoral immune responder vaccine administer study NCT00434512 . Subjects must willing accept HIV test result . Individuals elect receive test result enrol . Clinically significant laboratory value normal range blood urea nitrogen , creatinine , alanine aminotransferase aspartate aminotransferase , clinically significant laboratory value normal range Hemoglobin , per investigator judgment . Women pregnant breastfeeding . Receipt live attenuate vaccine within 30 day vaccination . Receipt medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) allergy treatment antigen injection ( include tuberculin skin test ) within &lt; = 21days preceding plan &lt; = 21 day follow study vaccine administration . Receipt blood product 120 day prior vaccination . Receipt immunoglobulin 120 day prior vaccination . Subject donate blood last 3 month . Bleeding disorder diagnose physician ; e.g. , factor deficiency , coagulopathy platelet disorder require special precaution . Chronic administration immunosuppressant immunemodifying drug within six month prior first . History serious adverse reaction vaccine include anaphylaxis relate symptom hive , respiratory difficulty , angioedema abdominal pain . History reaction hypersensitivity likely exacerbate component vaccine/product . History serious allergic reaction substance require hospitalization emergency medical care . History hypersensitivity chloroquine component drug . History hypersensitivity aminoglycosides . Ophthalmologic finding screen . Previous administration 4aminoquinoline previous year duration 1 year . History Glucose6Phosphate Dehydrogenase deficiency . History hematopoietic disease . History Myasthenia gravis . History serious neurological disorder seizure . History immunodeficiency immunemediated disorder , include active psoriasis . History type I type II diabetes mellitus include case control diet alone . Thyroid disease include history thyroidectomy diagnose require medication . Asthma require daily steroid long act Î²agonist prevention . Unstable asthma define : Sudden acute attack occur less three hour without obvious trigger . Hospitalization asthma last two year . Food wineinduced asthma . Known sensitivity sulfites aspirin . History major congenital defect . History chronic fatigue syndrome fibromyalgia . History malignancy . Splenectomy . Morbid obesity . Clinically relevant hypertension . Subjects history , current , alcohol substance abuse . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous inclusion HIV vaccines trial study NCT00434512 . Subject seropositive HIV , determine test result perform .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>52 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Chloroquine</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>